



13 February 2019

ASX ANNOUNCEMENT

SOZO® CHF Manuscript Published in Key Cardiology Journal

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announced that the full manuscript of the previously announced abstract *Correlation of Limb Bioimpedance to Echocardiographic Indicators of Congestion in Patients with NYHA Class II/III Heart Failure* has been published in the *Cardiology and Vascular Research* journal.

The manuscript's conclusions state "Preliminary findings demonstrated excellent correlations with BIS measurements and [inferior vena cava] IVC size, right atrial pressure and pulmonary artery systolic pressure measurements which suggest a possible alternative method to detect fluid overload despite the small sample size. Trending a patient's impedance using the SOZO® device at home or the practitioner's office may assist clinicians in providing more accurate, individualized [heart failure] HF care."

Richard Carreon, Managing Director and CEO of ImpediMed said "We continue to add to the positive clinical evidence for the use of SOZO in the management of heart failure. SOZO is the only BIS device CE Marked and FDA-cleared for monitoring fluid status in patients living with heart failure in a clinical or at-home environment. We believe SOZO's ability to accurately and noninvasively measure and monitor small fluid changes in the human body has the potential to greatly improve these patients' lives while also providing tremendous savings to the healthcare system."

Cardiology & Vascular Research is a scientific, peer-reviewed international journal devoted to cardiovascular research. The scope of the journal covers a broad spectrum of

For personal use only

Cardiovascular Pathology, Epidemiology, Genomics, Cardiovascular Pharmacology, Translational Cardiology and vascular and lymphatic research, including vascular structure, vascular function, hemodynamics, mechanics, cell signaling, intercellular communication, growth, and differentiation.

Link to article: <http://scivisionpub.com/pdfs/correlation-of-limb-bioimpedance-to-echocardiographic-indicators-of-congestion-in-patients-with-nyha-class-iiii-heart-failure-651.pdf>

Richard Carreon
Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.